Business
Equillium to Present at the Wells Fargo Healthcare Conference and the H.C. Wainwright 26th Annual Global Investor Conference
LA JOLLA, Calif.--(BUSINESS WIRE)-- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to
About this update from Equillium, Inc.
[{"type":"text","content":" LA JOLLA, Calif.--(BUSINESS WIRE)--\nEquillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that it will present and host investor meetings at the Wells Fargo Healthcare Conference and H.C. Wainwright’s 26th Annual Global Investor Conference.\n\n\nManagement will provide an overview of the Company’s multi-cytokine inhibitor programs and platform, currently focused on dermatological and gastrointestinal indications, as well as the ongoing development of itolizumab in partnership with Ono Pharmaceutical and Ono’s pending option exercise decision to potentially acquire Equillium’s rights to itolizumab. Management will be available for one-on-one meetings during both conferences.\n\n\n\n\nConference:\n\n\n\n\n\n\n\n\nWells Fargo Healthcare Conference\n\n\n\n\n\n\n\n\nLocation:\n\n\n\n\n\n\n\n\nEncore Boston Harbor\n\n\n\n\n\n\n\n\nDates:\n\n\n\n\n\n\n\n\nWednesday, September 4 – Friday, September 6\n\n\n\n\n\n\n\n\nPresentation:\n\n\n\n\n\n\n\n\nThursday, September 5, 1:30 pm Pacific Time | 4:30 pm Eastern Time\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\nConference:\n\n\n\n\n\n\n\n\nH.C. Wainwright, 26th Annual Global Investor Conference\n\n\n\n\n\n\n\n\nLocation:\n\n\n\n\n\n\n\n\nLotte New York Palace Hotel\n\n\n\n\n\n\n\n\nDates:\n\n\n\n\n\n\n\n\nMonday, September 9 – Wednesday, September 11\n\n\n\n\n\n\n\n\nPresentation:\n\n\n\n\n\n\n\n\nTuesday, September 10, 5:00 am Pacific Time | 8:00 am Eastern Time\n\n\n\n\n\n\n\nWebcast access for both conferences will be available on the Events & Presentations page under the Investor Relations tab on the Company’s website. An archived replay of both presentations will be available for 90 days.\n\n\nAbout Equillium\n\n\nEquillium is a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need. The company’s pipeline consists of the following novel first-in-class immunomodulatory assets and product platform targeting immuno-inflammatory pathways. EQ101: a selective tri-specific cytokine inhibitor targeting IL-2, IL-9, and IL-15; recently announced positive results from a Phase 2 pr...